Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
Public ClinicalTrials.gov record NCT01532687. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma
Study identification
- NCT ID
- NCT01532687
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Enrollment
- 54 participants
Conditions and interventions
Conditions
- Adult Alveolar Soft Part Sarcoma
- Adult Angiosarcoma
- Adult Desmoplastic Small Round Cell Tumor
- Adult Epithelioid Hemangioendothelioma
- Adult Epithelioid Sarcoma
- Adult Extraskeletal Myxoid Chondrosarcoma
- Adult Extraskeletal Osteosarcoma
- Adult Fibrosarcoma
- Adult Leiomyosarcoma
- Adult Liposarcoma
- Adult Malignant Peripheral Nerve Sheath Tumor
- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Adult Undifferentiated Pleomorphic Sarcoma
- Malignant Adult Hemangiopericytoma
- Recurrent Adult Soft Tissue Sarcoma
- Sarcoma
- Stage III Adult Soft Tissue Sarcoma AJCC v7
- Stage IV Adult Soft Tissue Sarcoma AJCC v7
Interventions
- Gemcitabine Drug
- Gemcitabine Hydrochloride Drug
- Laboratory Biomarker Analysis Other
- Pazopanib Drug
- Pazopanib Hydrochloride Drug
- Placebo Administration Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 12, 2012
- Primary completion
- Oct 30, 2019
- Completion
- Oct 30, 2019
- Last update posted
- Sep 26, 2021
2012 – 2019
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01532687, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 26, 2021 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01532687 live on ClinicalTrials.gov.